Clinical Trials Logo

Filter by:
NCT ID: NCT05327127 Recruiting - NASH Clinical Trials

Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis

Start date: November 14, 2022
Phase: Phase 2
Study type: Interventional

A study to investigate the use of combination therapy with two investigational products for the treatment of adult patients with Nonalcoholic steatohepatitis (NASH).

NCT ID: NCT05327114 Recruiting - Clinical trials for Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Start date: September 23, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

The main purpose of this study is to evaluate the safety and efficacy of nipocalimab compared to placebo in delaying relapse in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who initially respond to nipocalimab in Stage A.

NCT ID: NCT05326347 Recruiting - Schizophrenia Clinical Trials

A Long-term Administration Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia

Start date: May 31, 2022
Phase: Phase 3
Study type: Interventional

Confirm the tolerability and safety of long-term administration of the brexpiprazole QW formulation in patients with schizophrenia

NCT ID: NCT05326230 Recruiting - Hypertension Clinical Trials

A Clinical Study of the Paradiseā„¢ Renal Denervation System in Patients With Hypertension (RADIANCE-HTN DUO)

Start date: July 1, 2022
Phase: N/A
Study type: Interventional

To compare the antihypertensive effect of renal denervation with the Paradiseā„¢ system with that of a sham procedure in hypertensive patients receiving two antihypertensive drugs at the time of consent, and treated with a duo combination antihypertensive pill.

NCT ID: NCT05325866 Recruiting - Solid Tumors Clinical Trials

A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

FORTITUDE-301
Start date: September 23, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objectives of this study are to observe the safety and tolerability of bemarituzumab and to evaluate preliminary antitumor activity.

NCT ID: NCT05325645 Recruiting - Acute Schizophrenia Clinical Trials

Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia

Start date: June 21, 2022
Phase: Phase 3
Study type: Interventional

Confirm the efficacy of the brexpiprazole QW formulation versus placebo for acute symptoms of schizophrenia

NCT ID: NCT05325034 Recruiting - Clinical trials for Cardiovascular Diseases

Guideline Oriented Approach To Lipid Lowering In Asia-Pacific

GOAL-ASIA
Start date: September 15, 2022
Phase: N/A
Study type: Interventional

Multinational, patient-level randomised, multi-phase standard-of-care control arm, parallel group, implementation study. Patients will be recruited during hospitalisation and be randomised to a multifaceted intervention to be delivered either 'early' (baseline) or 'late' (6 months), in a 1:1 fashion.

NCT ID: NCT05324436 Recruiting - Clinical trials for Mesothelioma, Malignant

A Study of Yervoy and Opdivo Combination Therapy in Participants With Unresectable Advanced/Recurrent Malignant Pleural Mesothelioma (MPM)

Start date: January 8, 2022
Phase:
Study type: Observational

The purpose of this study is to observe the safety of the combination therapy with Yervoy and Opdivo in Japanese participants for the treatment of unresectable advanced/recurrent malignant pleural mesothelioma (MPM).

NCT ID: NCT05322577 Recruiting - Gastric Cancer Clinical Trials

A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.

FORTITUDE-103
Start date: May 17, 2022
Phase: Phase 1
Study type: Interventional

The main objectives of this study are to evaluate the safety and tolerability of bemarituzumab in combination with other anti-cancer therapies, and to evaluate the efficacy of bemarituzumab in combination with S-1 and oxaliplatin (SOX) and nivolumab as assessed by objective response.

NCT ID: NCT05319730 Recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

Start date: May 16, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2, multicenter, randomized, open-label umbrella platform study to evaluate the safety and efficacy of investigational agents with or without pembrolizumab and/or chemotherapy, for the treatment of participants with second line (2L) esophageal squamous cell carcinoma (ESCC) who have previously been exposed to PD-1/PD-L1 based treatment.